These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1462041)

  • 1. [Recent findings on the pathogenesis and therapy of anemia in chronic kidney failure].
    Moccia F; Morra L; Gurreri G
    Recenti Prog Med; 1992 Oct; 83(10):572-6. PubMed ID: 1462041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of erythroid inhibiting factors (EIF) in patients with anemia of chronic renal failure.
    Radtke HW; Rege AB; LaMarche M; Fisher JW
    Proc Clin Dial Transplant Forum; 1979; 9():179-83. PubMed ID: 552040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of erythropoiesis in chronic uremic patients treated with intermittent hemodialysis.
    Morra L; Ponassi A; Gurreri G; Moccia F; Caristo G; Mela GS; Sacchetti C
    Biomed Pharmacother; 1987; 41(7):396-9. PubMed ID: 3446291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
    Rozental' RL; Zezina LIu; Spudass AV
    Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of BPA secretory ability from blood mono-nuclear cells in uremic patients after renal transplantation or rEpo treatment].
    Abe T; Kawano Y; Takaue Y; Watanabe T; Kuroda Y; Ninomiya T; Minakuchi J; Kawashima S
    Rinsho Ketsueki; 1990 Apr; 31(4):438-42. PubMed ID: 2381057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states.
    Urabe A; Saito T; Fukamachi H; Kubota M; Takaku F
    Int J Cell Cloning; 1987 May; 5(3):202-8. PubMed ID: 3598244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia of chronic renal failure: inhibition of erythropoiesis by uremic serum.
    Freedman MH; Cattran DC; Saunders EF
    Nephron; 1983; 35(1):15-9. PubMed ID: 6888621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 11. [Current aspects of the pathogenesis and therapy of anemia in chronic kidney failure].
    Kirov Ch; Koĭchev A
    Vutr Boles; 1989; 28(6):13-6. PubMed ID: 2699126
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of erythroid colony-forming cells (CFU-E and BFU-E) in sera of azotemic patients with anemia of renal disease.
    Ohno Y; Rege AB; Fisher JW; Barona J
    J Lab Clin Med; 1978 Dec; 92(6):916-23. PubMed ID: 739170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anemia in patients with chronic kidney failure undergoing systematic hemodialysis treatment].
    Landar' VA; Sarycheva TG; Shemetov VD; Kozinets GI
    Urol Nefrol (Mosk); 1989; (1):54-5. PubMed ID: 2718284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin.
    Brunati C; Cappellini MD; De Feo T; Guastoni C; Ballerini L; Busnach G; Civati G; Fiorelli G; Minetti L
    Am J Nephrol; 1992; 12(1-2):9-13. PubMed ID: 1415372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheological properties of red blood cells (including reticulocytes) in patients with chronic renal disease.
    Nowak E; Wyrwicz G; Dabrowski Z; Smoleńiski O; Spodaryk K
    Clin Hemorheol Microcirc; 1999; 21(2):87-94. PubMed ID: 10599591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ca++ and 1,25(OH)2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients.
    Carozzi S; Ramello A; Nasini MG; Schelotto C; Caviglia PM; Cantaluppi A; Salit M; Lamperi S
    Adv Perit Dial; 1990; 6():312-5. PubMed ID: 1982836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
    Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
    Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.